Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-654-5 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
A key study for oral acute toxicity was performed in mice, demonstrating LD50 of 11000 mg/kg bw. A key study for dermal acute toxicity was available from read across substance Butanedioic acid, 2(or 3)-sulfo-, 4-[2-[(1-oxo(C12-C18(even numbered) and C18unsaturated)alkyl))amino]ethyl]esters, disodium salts, showing LD50 >2000 mg/kg bw. Inhalation toxicity testing was waived based upon the fact that acute inhalation exposure as such is very unlikely for sulphosuccinates due to their substance properties and the risk management measures that are already implemented.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1967
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- yes
- Remarks:
- 7 days instead of 14 days observation
- Principles of method if other than guideline:
- Single oral application to mice and calculation of 7 day LD50
Study performance before implementation of corresponding international guidelines, however study performance is comparable to recent guidelines to great extent. - GLP compliance:
- no
- Remarks:
- study performance before implementation of GLP
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- mouse
- Strain:
- NMRI
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Institut für industrielle und biologische Forschung, GmbH, Köln
- Age at study initiation: Not provided
- Weight at study initiation: Median weight of 23.7 g
- Fasting period before study: Approximately 17-20 hours
- Housing: Prior to the application in Plastibox cages (42x28x17 cm3) in groups of 35 animals on vermiculite. After application in Makrolon cages on wire roasting over vermiculite.
- Diet (e.g. ad libitum): Altromin R, pellet diameter 8-9mm, supplier: Altromin GmbH
- Water (e.g. ad libitum): Tap water, ad libitum
- Acclimation period: Not provided
ENVIRONMENTAL CONDITIONS
- Temperature (°C): ca. 21°C
- Humidity (%): ca. 70%
- Air changes (per hr): Not provided
- Photoperiod (hrs dark / hrs light): Not provided - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 0.0464, 0.215, 0.464, 1.00, 1.00 and 1.00 (mL/mL) at the dose levels of 1.00, 4.64, 10.0, 21.5, 31.6 and 46.4 mL/kg bw, respectively
MAXIMUM DOSE VOLUME APPLIED: 46.4 mL/kg bw or rather 1.10 mL/mouse - Doses:
- 1.00 mL/kg bw; 4.64 mL/kg bw ; 10.0 mL/kg bw ; 21.5 mL/kg bw ; 31.6 mL/kg bw and 46.4 mL/kg bw
- No. of animals per sex per dose:
- 10 for the 1.00; 4.64; and 10.0 mL/kg dose
20 for the 21.5 and 46.4 mL/kg dose
16 for the 31.6 mL/kg dose - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days
- Frequency of observations and weighing: The mice were observed after application about 8 hours long at short intervals. Further assessments were performed several times daily until 7 days after application.
- Necropsy of survivors performed: yes
- Other examinations performed: vitality, pain reflex, cyanosis, breathing, corneal reflex, lid wide, exophtalmus, sound sensitivity, shaky walking, abdominal position, side position, running motion, clonic-tonic convulsions, ophistotonos, defecation; necropsy of deceased animals - Statistics:
- The quantitative evaluation of the lethality data was performed by graphical determination of the LD50 7 days after application, in the probability grid with logarithmic shared X-axis, when using confidence limits.
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 28.7 mL/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: LD50 as reported in study report referring to the test substance as delivered by the sponsor
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- ca. 11 000 mg/kg bw
- Based on:
- other: solid content
- Remarks on result:
- other: Recalculated LD50 referring to solid content of 39% (according to producer information) and an assumed density of roughly 1
- Mortality:
- Up to and including the dose level of 10.0 mL/kg bw no animal died.
In the dose group of 21.5 mL/kg bw 5% (1/20) of the animals was found death two days p.a.. In the dose groups of 31.6 and 46.4 mL/kg bw 88% (14/16) and 100% (20/20) of the animals died within 24 hours or 6 hours p.a. respectively. - Clinical signs:
- other: Especially in the doses 21.5; 31.6 and 46.6 mL/kg quiet, apathetic behavior, closed eyes, diarrhea with soft faeces and decreased sound sensitivity were observed. Also in the 10.0 mL/kg dose group a number of animals showed diarrhea ( occurrence ca. 2 hou
- Gross pathology:
- In the stomach and small intestine of mice who died, dark reddish-brown slimy liquid was determined. The mucous membranes were dark red and translucent, and showed macroscopic signs of irritation, especially the main gastric membranes. Intubation injuries were not found.
- Other findings:
- - Organ weights: no data
- Histopathology: no data
- Potential target organs: no data
- Other observations: no data - Interpretation of results:
- GHS criteria not met
- Conclusions:
- The LD50 at 7 days was 28.7mL/kg. The LD50 for an observation period of 24 hours did practically not differ from the previous value. Recalculated LD50 referring to solid content of 39% (according to producer information) and an assumed density of roughly 1 was calculated to be ca. 11000 mg/kg bw.
- Executive summary:
Acute oral toxicity (LD50) of the test item was examined by gavage in male NMRI mice at doses of 1, 4.64, 10, 21.5, 31.6 and 46.4 mL/kg bw. There were no pronounced , specific toxic behavioral symptoms registered at the lower doses of 1 and 4.64 mL/kg bw. At doses ≥10 ml/kg diarrhea was seen. The died mice showed irritation of the mucous membranes of the stomach and small intestine. At the higher doses (21.5, 31.6 and 4.64 mL/kg bw/day), quiet apathetic behaviour, closed eyes and decreased sound activity were also observed.
The LD50 at 7 days was 28.7 mL/kg. Recalculated LD50 referring to solid content of 39% (according to producer information) and an assumed density of roughly 1 was calculated to be ca. 11000 mg/kg bw.
Reference
Table 1. Lethality, chronological categorization (summed up, %)
Experimental Period |
Dosis (mL/kg) |
|||||
0 bis |
1.00 |
4.64 |
10.0 |
21.5 |
31.6 |
46.4 |
20 min |
|
|
|
|
6 |
|
40 min |
|
|
|
|
13 |
35 |
60 min |
|
|
|
|
19 |
60 |
2 h |
|
|
|
|
44 |
70 |
4 h |
|
|
|
|
50 |
90 |
6 h |
|
|
|
|
|
100 |
24 h |
0 |
0 |
0 |
0 |
88 |
100 |
2 d |
|
|
|
5 |
|
|
3 d |
|
|
|
|
|
|
4 d |
|
|
|
|
|
|
5 d |
|
|
|
|
|
|
6 d |
|
|
|
|
|
|
7 d |
0 |
0 |
0 |
5 |
88 |
100 |
Number of mice used |
10 |
10 |
10 |
20 |
16 |
20 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 11 000 mg/kg bw
- Quality of whole database:
- Reliable (Klimisch 2)
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- the study does not need to be conducted because exposure of humans via inhalation is not likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- other: CD/Crl:CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, 97633 Sulzfeld, Germany
- Age at study initiation: At dosing: Males: approx. 8 weeks; Females: Approx. 9 weeks
- Weight at study initiation: At dosing: Males: 215 - 237 g; Females: 217 – 239 g
- Fasting period before study: Approx. 16 hours before administration (only tap water was then available ad libitum)
- Housing: During the 14-day observation period the animals were kept in groups of 3 animals in MAKROLON cages ( type III plus) . Granulated textured wood (Granulat A2, J. Brandenburg, 49424 Goldenstedt, Germany)
- Diet (e.g. ad libitum): Commercial diet, ssniff® R/M-H V1534 (ssniff Spezialdiäten GmbH, 59494 Soest, Germany)
- Water (e.g. ad libitum): Drinking water in bottles was offered ad libitum.
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22°C ± 3°C (maximum range)
- Humidity (%): 55% ± 15% (maximum range)
- Air changes (per hr): Not provided
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: July 18, 2012 To: August 6, 2012 - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: The shaved intact dorsal skin, between the fore and hind extremities
- % coverage: 5 cm x 6 cm, approx. 1/10 of body surface
- Type of wrap if used: The test item was held in contact with the skin with 8 layers of gauze. The gauze was covered with a plastic sheet and secured with adhesive plaster strips (Omniplast (P. HARTMANN AG, 89522 Heidenheim, Germany) on the application site for 24 hours
REMOVAL OF TEST SUBSTANCE
- Washing (if done): No
TEST MATERIAL
- Amount(s) applied (volume or weight with unit) 4.22 mL/kg bw
- Constant volume or concentration used: yes - Duration of exposure:
- 24 hours
- Doses:
- 1 dose group (Limit test): 2000 mg/kg bw (dose level refers to the solids ingredients of the test item)
- No. of animals per sex per dose:
- 5
- Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations were performed before and immediately, 5, 15, 30 and 60 min, as well as 3, 6 and 24 hours after administration. All animals were observed for a period of 14 days. Individual body weights were recorded before administration of the test item and thereafter in weekly intervals up to the end of the study. Changes in weight were calculated and recorded.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs (changes of skin and fur, eyes and mucous membranes, respiratory and the circulatory, autonomic and central nervous system and somatomotor activity as well as behaviour pattern; tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma), body weight, gross pathology - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- act. ingr.
- Mortality:
- None of the animals died prematurely.
- Clinical signs:
- other: Under the present test conditions, a single dermal administration of 2000 mg Butanedioic acid, 2(or 3)-sulfo-, 4-[2-[(1- oxo(C12-C18(even numbered) and C18unsaturated)alkyl))amino]ethyl]esters, disodium salts/kg bw to rats revealed no signs of toxicity.
- Gross pathology:
- No macroscopic findings were observed at necropsy.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- According to the EC-Commission directive 67/548/EEC and its subsequent amendments on the approximation of the laws, regulations and administrative provision relating to the classification, packaging and labelling of dangerous substances and the results obtained under the present test conditions,Butanedioic acid, 2(or 3)-sulfo-, 4-[2-[(1- oxo(C12-C18(even numbered) and C18unsaturated)alkyl))amino]ethyl]esters, disodium salts requires no labeling (as LD50 > 2000 mg/kg).
Also, according to the EC Regulation 1272/2008 and subsequent regulations, the test material is not classified for acute dermal toxicity. - Executive summary:
In this experiment, Butanedioic acid, 2(or 3)-sulfo-, 4-[2-[(1- oxo(C12-C18(even numbered) and C18unsaturated)alkyl))amino]ethyl]esters, disodium salts was examined for acute toxicity after a single dermal application to rats. One dose level of 2000 mg/kg bw was administered on the shaved intact dorsal skin, between the fore and hind extremities of 5 male and 5 female CD/Crl:CD(SD) rats. The test item was held in contact with the skin with 8 layers of gauze. The gauze was covered with a plastic sheet and secured with adhesive plaster strips on the application site for 24 hours. All animals were observed for a period of 14 days. Under the present test conditions, a single dermal administration of 2000 mg active ingredient/kg bw to rats revealed no signs of toxicity and no deaths. All animals gained the expected body weight throughout the whole experimental period. No macroscopic findings were observed at necropsy.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Reliable (Klimisch 2)
Additional information
Acute oral toxicity
- In a key acute oral toxicity study, the registered substance was examined by gavage in male NMRI mice at doses of 1, 4.64, 10, 21.5, 31.6 and 46.4 mL/kg bw (Hackenberg, 1967). There were no very pronounced, specific toxic behavioral symptoms registered at the lower doses of 1 and 4.64 mL/kg bw. At doses ≥10 mL/kg diarrhea was seen. The died mice showed irritation of the mucous membranes of the stomach and small intestine. At the higher doses (21.5, 31.6 and 4.64 mL/kg bw/day), quiet apathetic behaviour, closed eyes and decreased sound activity were also observed. The LD50 at 7 days was 28.7 mL/kg. Recalculated LD50 referring to solid content of 39% (according to producer information) and an assumed density of roughly 1 was calculated to be ca. 11000 mg act. ingr./kg bw which is above limit dose.
- A supporting oral acute toxicity study in rats with read-across substance ' Butanedioic acid, 2 (or 3) - sulfo-, 4 - [2- [(1-oxo (C12 - C18 (even numbered) and C18unsaturated) alkyl)) amino] ethyl] esters, disodium salts' tested at 2000 mg active ingredient/kg bw did not reveal any signs of toxicity. (Haferkorn, 2013a) No death was recorded within the 14 days observation period. All animals gained the expected weight throughout the whole study period. No pathological changes were observed at necropsy. The LD50value was ranked exceeding 2000 mg/kg bw.
In conclusion there is no hazard for oral acute toxicity with registered substance.
Acute dermal toxicity
For the acute dermal toxicity testing, no test data were available for current substance, however read across data were available from 'Butanedioic acid, 2(or 3)-sulfo-, 4-[2-[(1-oxo(C12-C18(even numbered) and C18unsaturated)alkyl))amino]ethyl]esters, disodium salts'.
Justification for read across within the N2 (& N3) subgroup of sulfosuccinates is documented in a separate document attached in Section 13. A key dermal toxicity study with that test item containing 41.5% active ingredient was performed at one dose level of 2000 mg active ingredient/kg bw administered on the shaved intact dorsal skin of 5 male and 5 female CD/Crl:CD(SD) rats (Haferkorn, 2013b). The test item was held in contact with the skin under occlusive dressing for 24 hours. All animals were observed for a period of 14 days. The test item revealed no signs of toxicity and no deaths. All animals gained the expected body weight throughout the whole experimental period. No macroscopic findings were observed at necropsy.
In conclusion it can be assumed that there is no hazard for dermal acute toxicity with registered substance.
Acute inhalation toxicity
Inhalation is very unlikely due to large particle size, low vapour pressure and high hydrophilic properties of the substance. Based on these and other physicochemical properties, the inhalation route is not appropriate; the oral and dermal route of administration are therefore applied as first and second relevant routes (ECHA R7a Guidance p 342). Additional inhalation testing would therefore neither lead to a better risk assessment, nor improve the safety of applications. On the basis of the argumentation summarized above an acute inhalation toxicity study is waived.
Conclusion
- No hazard was identified for acute oral and dermal toxicity based on read-across and registered substances.
- Inhalation toxicity testing was waived based upon the fact that acute inhalation exposure as such is very unlikely.
- Further read-across information in provided in Section 13.
Justification for classification or non-classification
Based on these results and according to CLP (No. 1272/2008 of 16 December 2008), the test substance does not have to be classified and has no obligatory labelling requirement for acute oral and dermal toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.